, Volume 192, Issue 3, pp 441–448

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

  • Michael Poyurovsky
  • Camil Fuchs
  • Artashez Pashinian
  • Aya Levi
  • Sarit Faragian
  • Rachel Maayan
  • Irit Gil-Ad
Original Investigation



Search for safe and effective strategies to diminish weight gain associated with second generation antipsychotics (SGAs) is imperative. In the present study, we sought to replicate our preliminary findings, which indicated that coadministration of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain.

Materials and method

Fifty-nine patients hospitalized for first-episode DSM-IV schizophrenic disorder participated in this randomized double-blind study. Reboxetine (4 mg/day; 31 patients) or placebo (29 patients) was coadministered with olanzapine (10 mg/day) for 6 weeks. Analysis was by intention-to-treat.


Nine patients in each group prematurely discontinued the trial. Olanzapine/reboxetine-treated patients showed a significantly lower increase in body weight (mean = 3.31 kg, SD = 2.73) than their olanzapine/placebo-treated counterparts (mean = 4.91 kg, SD = 2.45). Significantly fewer olanzapine/reboxetine-treated patients gained at least 7% of their initial weight, the cutoff for clinically significant weight gain (6 [19.4%] of 31 patients vs 13 [46.4%] of 28 patients). Seven (22.6%) olanzapine/reboxetine-treated patients compared to only one patient (3.6%) in the olanzapine/placebo group revealed no weight change or even modest weight loss. Appetite increase was significantly lower in the olanzapine/reboxetine than olanzapine/placebo group and was correlated with attenuation of weight gain. Reboxetine addition was safe and well tolerated.


The results confirm that coadministration of reboxetine promotes a clinically meaningful attenuation of olanzapine-induced weight gain in schizophrenia patients. If substantiated in long-term studies, along with behavioral management and diet counseling, reboxetine may have a clinical utility in controlling SGA-induced weight gain.


Second generation antipsychotics Olanzapine Reboxetine Weight gain 


  1. Andreasen NC (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa CityGoogle Scholar
  2. Andreasen NC (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa CityGoogle Scholar
  3. Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ (2005) Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5(1):3PubMedCrossRefGoogle Scholar
  4. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedGoogle Scholar
  5. Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L (2004) Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37:206–210PubMedCrossRefGoogle Scholar
  6. Bishop JR, Ellingrod VL, Moline J, Miller D (2006) Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 12:BR47–BR50 (Epub 2006 Jan 26)PubMedGoogle Scholar
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107–122PubMedCrossRefGoogle Scholar
  8. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29:607–614CrossRefGoogle Scholar
  9. Elman I, Borsook D, Lukas SE (2006) Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31:2091–2120PubMedCrossRefGoogle Scholar
  10. First MB, Spitzer RL, Gibbon M (1995) Structured clinical interview for DSM-IV Axis I disorders, Patient Edition (SCID-I/P, version 2.0). Biometric Research, New York State Psychiatric Institute, New York, NYGoogle Scholar
  11. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055–1057PubMedCrossRefGoogle Scholar
  12. Guy W (1976) ECDE assessment manual for psychopharmacology. Revised DHEW Pub (ADM). National Institute of Mental Health, Rockville, MDGoogle Scholar
  13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedCrossRefGoogle Scholar
  14. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC (2005) A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 162:954–962PubMedCrossRefGoogle Scholar
  15. Kanders BS, Forse RA, Blackburn GL (1991) Methods in obesity. In: Rakel RE (ed) Conn’s current therapy. WB Saunders, Philadelphia, pp 524–532Google Scholar
  16. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92–100PubMedCrossRefGoogle Scholar
  17. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255–258PubMedCrossRefGoogle Scholar
  18. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519–526PubMedCrossRefGoogle Scholar
  19. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C (2006) Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 67:547–553PubMedCrossRefGoogle Scholar
  20. Newcomer JW, Haupt DW (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51:480–491PubMedGoogle Scholar
  21. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, Lim SW, Paik JW, Lee HJ (2006) Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 141:394–397PubMedGoogle Scholar
  22. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160:297–302PubMedCrossRefGoogle Scholar
  23. Schatzberg AF (2000) Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61(Suppl 10):31–38PubMedGoogle Scholar
  24. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl):11–19Google Scholar
  25. Spina E, Scordo MG, D’Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517–538PubMedCrossRefGoogle Scholar
  26. Ste Marie L, Luquet S, Curtis W, Palmiter RD (2005) Norepinephrine- and epinephrine-deficient mice gain weight normally on a high-fat diet. Obes Res 13(9):1518–1522PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Michael Poyurovsky
    • 1
    • 2
  • Camil Fuchs
    • 3
  • Artashez Pashinian
    • 1
  • Aya Levi
    • 1
  • Sarit Faragian
    • 1
  • Rachel Maayan
    • 4
  • Irit Gil-Ad
    • 4
  1. 1.Research UnitTirat Carmel Mental Health CenterTirat CarmelIsrael
  2. 2.Rappaport Faculty of MedicineIsrael Institute of Technology—TechnionHaifaIsrael
  3. 3.Department of Statistics and Operations ResearchTel-Aviv UniversityTel-AvivIsrael
  4. 4.Laboratory of Biological Psychiatry, Felsenstein Medical Research CenterGeha Psychiatric HospitalPetah TiqvaIsrael
  5. 5.Department of StatisticsUniversity of PittsburghPittsburghUSA

Personalised recommendations